← All Novo Integrated Sciences, INC filings

Novo Integrated Sciences, INC 8-K filings

OTC.Pink
NVOS
Novo Integrated Sciences, INC
8-K: Novo Integrated Sciences Subsidiary Signs Consulting Agreement with Futura Surgicare
Novo Integrated Sciences' subsidiary, Clinical Consultants International, has signed a consulting agreement with Futura Surgicare to assist with FDA approvals and introduce their surgical products to the North America market.
OTC.Pink
NVOS
Novo Integrated Sciences, INC
8-K: Novo Integrated Sciences Secures Limited Waiver on $70 Million Promissory Note Amid Nasdaq Compliance Issue
Novo Integrated Sciences received a limited waiver from a lender regarding a potential default on a $70 million promissory note due to a Nasdaq minimum bid price compliance issue.
OTC.Pink
NVOS
Novo Integrated Sciences, INC
8-K: Novo Integrated Sciences Appoints Robert Oliva as New President, Replacing Christopher David
Novo Integrated Sciences has appointed Robert Oliva as its new President, succeeding Christopher David, who remains as COO and a board member.
OTC.Pink
NVOS
Novo Integrated Sciences, INC
8-K: Novo Integrated Sciences Faces Nasdaq Delisting Threat Due to Low Share Price
Novo Integrated Sciences has received a notification from Nasdaq for not meeting the minimum bid price requirement, placing its listing at risk.
OTC.Pink
NVOS
Novo Integrated Sciences, INC
8-K: Novo Integrated Sciences Reports 14% Revenue Increase in Fiscal Q1 2024, Despite Widening Net Loss
Novo Integrated Sciences announced a 14% increase in revenue for the first fiscal quarter of 2024, but also reported a larger net loss compared to the same period last year.